Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Clinical trial NCT06201234 · RECRUITING

Trial details

NCT number: NCT06201234
Sponsor: GBG Forschungs GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hormone Receptor Positive HER-2 Negative Breast Cancer Advanced or Metastatic Breast Cancer BRCA1 Mutation BRCA2 Mutation

Start date: 2024-12-13
Primary completion: 2028-12-31
Enrollment: 176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.